99mTc-MAG3, a new renal imaging agent: Preliminary results in patients |
| |
Authors: | Andrew Taylor Jr. Dennis Eshima Naomi Alazraki |
| |
Affiliation: | (1) Division of Nuclear Medicine, Department of Radiology, Emory University Hospital, 1364 Clifton Road, N.E., 30322 Atlanta, GA, USA |
| |
Abstract: | 99mTc-mercaptoacetyltriglycine (MAG3) is a new renal radiopharmaceutical which has been shown to have biological properties similar to131I-hippurate (OIH) in animals and volunteers.99mTc-MAG3 has now been compared with131I-orthoiodohippurate (OIH) in a group of patients with varying degrees of renal impairment. In all cases, the99mTc-MAG3 images were superior regardless of serum creatinine. Selected examples are illustrated including scans and renogram curves in a normal volunteer, transplant patients with creatinines of 9.8 mg/dl and 2.6 mg/dl respectively, and a furosemide study in a patient with questionable obstruction. Our preliminary results suggest that99mTc-MAG3 performs well in patients with impaired renal function and may well provide an acceptable replacement for OIH. A kit formulation has been developed and will soon be undergoing clinical evaluation. |
| |
Keywords: | MAG3 Mercaptoacetyltriglycine 99mTc-Renal radiopharmaceuticals OIH 131I-orthoiodohippurate |
本文献已被 SpringerLink 等数据库收录! |
|